UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.

Ring Therapeutics, a US-based gene therapy developer, has secured $117m in a series B round backed by UPMC Enterprises, the commercialisation arm of University of Pittsburgh Medical Center, a health system closely aligned with the institution.
The round was also backed by Flagship Pioneering, Invus, Altitude Life Science Ventures, Partners Investment, funds and accounts advised by T Rowe Price Associates and unnamed others.
Founded in 2017 by Flagship Pioneering, Ring Therapeutics is working on anellovirus-based vector candidates for…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in